Cell Source, Inc. (CLCS) — SEC Filings
Cell Source, Inc. (CLCS) — 6 SEC filings. Latest: 8-K (Jun 27, 2025). Includes 3 10-Q, 2 8-K, 1 10-K.
View Cell Source, Inc. on SEC EDGAR
Overview
Cell Source, Inc. (CLCS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Jun 27, 2025: On June 26, 2025, Cell Source, Inc. filed an 8-K to report a change in its certifying accountant. The company has appointed Citrin Cooperman & Co., LLP as its new independent registered public accounting firm, replacing Rosenberg Rich Baker Berman & Company.
Sentiment Summary
Across 6 filings, the sentiment breakdown is: 6 neutral. The dominant filing sentiment for Cell Source, Inc. is neutral.
Filing Type Overview
Cell Source, Inc. (CLCS) has filed 2 8-K, 3 10-Q, 1 10-K with the SEC between Apr 2024 to Jun 2025.
Filings by Year
Recent SEC Filings (6)
| Date | Form | Description | Risk |
|---|---|---|---|
| Jun 27, 2025 | 8-K | Cell Source, Inc. Appoints New Auditor | low |
| Nov 14, 2024 | 10-Q | Cell Source, Inc. Files Q3 2024 10-Q | low |
| Aug 19, 2024 | 10-Q | Cell Source, Inc. Files 10-Q for Q2 2024 | low |
| Jul 29, 2024 | 10-Q | Cell Source, Inc. Files Q1 2024 10-Q | low |
| Jun 24, 2024 | 10-K | Cell Source, Inc. Files 2023 Annual Report | low |
| Apr 9, 2024 | 8-K | Cell Source, Inc. Files 8-K Under 'Other Events' | medium |
Risk Profile
Risk Assessment: Of CLCS's 6 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 5 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Top Tags
pharmaceuticals (4) · 10-Q (3) · financials (2) · auditor-change (1) · 8-k (1) · company-information (1) · annual-report (1) · 8-K (1) · other-events (1) · corporate-action (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reporting Period End Date | 2024-03-31 | Indicates the end of the fiscal quarter for which financial data is reported. |
| Filing Date | 2024-07-29 | The date the 10-Q was officially submitted to the SEC. |
Frequently Asked Questions
What are the latest SEC filings for Cell Source, Inc. (CLCS)?
Cell Source, Inc. has 6 recent SEC filings from Apr 2024 to Jun 2025, including 3 10-Q, 2 8-K, 1 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CLCS filings?
Across 6 filings, the sentiment breakdown is: 6 neutral. The dominant sentiment is neutral.
Where can I find Cell Source, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cell Source, Inc. (CLCS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cell Source, Inc.?
Financial highlights for Cell Source, Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for CLCS?
Investment thesis data for CLCS will be available once enriched filings are processed.
Who are the key executives at Cell Source, Inc.?
Executive information for Cell Source, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Cell Source, Inc. stock?
Of CLCS's 6 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Cell Source, Inc.?
Forward guidance and predictions for Cell Source, Inc. are extracted from SEC filings as they are enriched.